Insider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Sells 5,214 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Yakob Liawatidewi sold 5,214 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total transaction of $271,388.70. Following the sale, the executive vice president now owns 74,938 shares in the company, valued at approximately $3,900,522.90. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Amphastar Pharmaceuticals Trading Up 4.8 %

Amphastar Pharmaceuticals stock opened at $48.31 on Friday. Amphastar Pharmaceuticals, Inc. has a 52-week low of $36.56 and a 52-week high of $65.92. The company has a market cap of $2.35 billion, a P/E ratio of 15.43, a P/E/G ratio of 0.97 and a beta of 0.82. The company has a quick ratio of 2.63, a current ratio of 3.52 and a debt-to-equity ratio of 0.82. The business has a 50-day simple moving average of $48.44 and a two-hundred day simple moving average of $44.19.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Wednesday, August 7th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.10. Amphastar Pharmaceuticals had a net margin of 23.36% and a return on equity of 29.79%. The company had revenue of $182.39 million during the quarter, compared to analyst estimates of $171.29 million. Analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.67 EPS for the current year.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Hedge funds have recently modified their holdings of the business. TD Asset Management Inc lifted its position in Amphastar Pharmaceuticals by 67.4% during the second quarter. TD Asset Management Inc now owns 1,691,569 shares of the company’s stock valued at $67,663,000 after purchasing an additional 680,976 shares in the last quarter. Boston Trust Walden Corp purchased a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter valued at about $26,189,000. Millennium Management LLC grew its stake in shares of Amphastar Pharmaceuticals by 84.6% during the 2nd quarter. Millennium Management LLC now owns 738,748 shares of the company’s stock valued at $29,550,000 after acquiring an additional 338,653 shares during the period. Epoch Investment Partners Inc. increased its holdings in Amphastar Pharmaceuticals by 35.1% in the 2nd quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company’s stock worth $43,154,000 after acquiring an additional 280,390 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in Amphastar Pharmaceuticals during the 2nd quarter worth approximately $9,085,000. Institutional investors own 65.09% of the company’s stock.

Wall Street Analysts Forecast Growth

AMPH has been the subject of a number of research analyst reports. Piper Sandler reduced their target price on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Finally, StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $63.00.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.